Why pharma walked away
42:41–44:17 · 96s
Longo suggests GH secretagogues stalled because the data skewed negative—aging acceleration and disease risk—while GLP‑1s were commercially viable.
42:41–44:17 · 96s
Longo suggests GH secretagogues stalled because the data skewed negative—aging acceleration and disease risk—while GLP‑1s were commercially viable.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.